Skip to main content
Minnesota Department of Health logo
  • Main navigation

    • Home
    • Data, Statistics, and Legislation
    • Diseases and Conditions
    • Health Care Facilities, Providers, and Insurance
    • Healthy Communities, Environment, and Workplaces
    • Individual and Family Health
    • About Us
    • News and Announcements
    • Translated Materials

Main navigation mobile

  • Data, Statistics, and Legislation
  • Diseases and Conditions
  • Health Care Facilities, Providers, and Insurance
  • Healthy Communities, Environment, and Workplaces
  • Individual and Family Health
  • About Us
  • News and Announcements
  • Translated Materials
MDH Logo

Breadcrumb

  1. Home
  2. Diseases and Conditions
  3. Varicella (Chickenpox)
  4. Varicella Information For Health Professionals
Topic Menu

Varicella

  • Varicella Home
  • Basics
  • For Health Professionals
  • For Schools and Child Care
  • Statistics

Related Topics

  • Immunization
  • Shingles (Herpes Zoster)
  • Infectious Diseases A-Z
  • Reportable Infectious Diseases

Varicella

  • Varicella Home
  • Basics
  • For Health Professionals
  • For Schools and Child Care
  • Statistics

Related Topics

  • Immunization
  • Shingles (Herpes Zoster)
  • Infectious Diseases A-Z
  • Reportable Infectious Diseases
Contact Info
Infectious Disease Epidemiology, Prevention and Control Division
651-201-5414
IDEPC Comment Form

Contact Info

Infectious Disease Epidemiology, Prevention and Control Division
651-201-5414
IDEPC Comment Form

Post Exposure Prophylaxis (PEP) with Varicella Immune Globulin

About varicella immune globulin

Varicella immune globulin (VariZIG, Cangene Corporation, Winnipeg, Canada) was FDA-approved in 2013, and is recommended for post exposure prophylaxis (PEP) by the Advisory Committee on Immunization Practices (ACIP) for certain individuals who can't receive the vaccine. For maximum effect, it should be given as soon as possible, but can be given for up to 10 days post-exposure.

Candidates for VariZIG:

  • Are at high risk for severe varicella,
  • Have had an exposure likely to result in infection, and
  • Lack evidence of immunity to varicella.

Evidence of immunity to varicella includes:

  • Documented varicella vaccination.
  • Laboratory test for VZV IgG showing immunity, or laboratory confirmation of disease.
  • Documented history from a health care provider of diagnosis of varicella (chickenpox) or zoster (shingles), or verification of a history of varicella or zoster.

Groups of exposed individuals recommended to receive VariZIG:

  • Immunocompromised persons without evidence of immunity.
  • Newborns whose mothers have signs and symptoms of varicella within 5 days before delivery or within 2 days after delivery.
  • Premature infants born before 28 weeks of gestation or who weigh 1,000 g or less and were exposed during the neonatal period, regardless of evidence of maternal immunity.
  • Premature infants born after 28 weeks or more of gestation and who were exposed during the neonatal period, in the absence of maternal immunity.
  • Pregnant women without evidence of immunity.
Tags
  • varicella
Last Updated: 10/26/2022

Get email updates


Minnesota Department of Health logo

Privacy Policy
Equal Opportunity
Translated Materials
Feedback Form
About MDH
Minnesota.gov
  • Facebook
  • Twitter
  • Linked In
  • Instagram
  • Youtube
Minnesota Department of Health Minnesota Department of health print search share facebook instagram linkedin twitter youtube